about
Effect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancerGoserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision.FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After TreatmentChange in bone mineral density during adjuvant chemotherapy for early-stage breast cancer.Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cellsToll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.Effect of PI3K/Akt Signaling Pathway on the Process of Prostate Cancer Metastasis to Bone.Low-trauma fractures without osteoporosis.Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.Melphalan modifies the bone microenvironment by enhancing osteoclast formation.Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer.Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model.Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
P2860
Q35553550-091618B6-A874-4E89-81F2-F667AFE5CE21Q36661462-D770B4BE-9163-4BB6-8B36-1CF2CFE8DC03Q36677418-4E05013E-E19D-4263-943D-D3013B31541BQ36716103-9DFF7D7C-EA21-4D57-80DC-B201716C50DCQ37195016-ACCD854F-EDC7-449C-BFCD-78EE9EF71039Q37228831-ECA06F2F-849B-4A1D-ACA4-B1A1B9450A6CQ37699431-771EDFE2-670E-4194-A4AC-D40112D82F61Q38207463-0995A659-88A3-4EC6-B211-1BBB90B15B14Q38741507-827E7F27-088D-4472-ADE8-1B6FD7C29230Q38781061-751B0783-670C-4187-A10D-88DF73C86F4EQ38978699-F473A285-9750-4B32-8D64-F568A1BF3B41Q40280431-4A21BB4F-7435-4EE2-89F7-72A34D6B9E7EQ41555770-E2FCD590-592B-43AE-BC2B-0125057C5195Q42366597-63C54533-0D76-4564-A6C1-C8100A97BFF9Q47426563-9696528A-7C77-46A3-B159-A9DB1F1F9F5DQ47750908-A2A09B4C-7A19-42CC-81BC-EAD57D5DC096Q50682230-7792C762-A300-440F-9891-21536E50BF7F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of cancer treatment-induced bone loss.
@en
type
label
Management of cancer treatment-induced bone loss.
@en
prefLabel
Management of cancer treatment-induced bone loss.
@en
P2093
P2860
P356
P1476
Management of cancer treatment-induced bone loss.
@en
P2093
Emma Rathbone
Janet E Brown
Robert E Coleman
P2860
P2888
P304
P356
10.1038/NRRHEUM.2013.36
P407
P577
2013-03-19T00:00:00Z
P5875
P6179
1027882595